“Anthropic CEO Dario Amodei says AI could help cure most diseases within the next five to 10 years, and Claude AI helped identify a previously unknown biological system in bacteriophages called array-associated reverse transcriptases (ART) that has features resembling CRISPR" (Post headline as shown on the image: "Anthropic CEO says AI…”

On the Amodei statement. Amodei stated it himself, in his own words, on the record. In the X post accompanying the announcement he wrote that in Machines of Loving Grace he had written about AI's potential to "cure most diseases in 5-10 years", a goal that sounds impossible, but one he believes is just barely possible if AI is applied to every stage of the pipeline. He also repeated the prediction in his September 2026 essay: "I believe that AI could cure most major diseases in the next 5–10 years, greatly accelerate economic growth rates, create a world of abundance and empowerment". In the same essay he ties this to personal history, writing that his father died of a disease cured a few years after his death, and that he himself survived an early-stage cancer. On the discovery. Anthropic's own announcement states that after further analysis and testing in its lab, the team recognised the pattern as marking a previously uncharacterized enzyme system found in bacteriophages, which it calls array-associated reverse transcriptases (ART), with work to understand the primary function ongoing. On the process, Anthropic says it gave Claude a prompt to search a massive DNA sequence database for interesting new RTs, with its own involvement limited to the initial prompt and the lab work, and that after 21 hours of searching by roughly 950 agents using 210 million tokens, one agent spotted a repeating DNA pattern next to the gene for an odd-looking RT. The funnel matches the post's numbers: Claude agents gathered over 200,000 RTs, picked out 3,500 new candidate systems, and narrowed those to the 20 most compelling candidates, analysis Anthropic says would take an expert scientist weeks to months. On what is new versus already known. Anthropic itself draws the line: the underlying RT, found in a jumbo phage, had been identified in previous studies, and Claude appears to be the first to notice the system's defining features, an associated array of non-coding DNA sequences and an additional accessory protein of unknown function. An outside computer scientist put it the same way: "The enzyme itself was already known," Perrin explained in a piece for The Conversation. "What is new is the recognition that it may form part of this larger system." On the CRISPR resemblance and its limits. Reported structure from the preprint: ART has three parts, the enzyme, a partner gene beside it, and an array of evenly spaced DNA repeats, a layout that recalls CRISPR, where an array holds a bank of different RNA guides; per the preprint ART arrays hold 3 to 21 copies of a short repeat, and none has the cas genes that CRISPR systems carry nearby. The one physical result: in lab tests Anthropic's scientists found the array is read out as a set of distinct short RNAs, and in published data from a Staphylococcus phage these RNAs made up as much as 8% of the phage's RNA 15 minutes after infection. On outside reaction. A named reviewer supplied by Anthropic: Feng Zhang, one of the pioneers of CRISPR genome editing and a professor at MIT and the Broad Institute, reviewed the pre-print and called the identification of RNA-repeat arrays associated with reverse transcriptases "genuinely intriguing" and worthy of further investigation. Independent skepticism is on the record: Kevin Blake, a microbiologist at Washington University School of Medicine, told Al Jazeera that because the array is "CRISPR-like" some have leapt to conclude Anthropic discovered the next CRISPR, that CRISPR-the-technology is very different from CRISPR in nature, that it has long been known countless CRISPR-like sequences remain unidentified because millions of bacterial species are unstudied, and that "There's nothing to indicate this is a rival to CRISPR-the-technology, or could be developed into any kind of therapeutic or practical application." Bloomberg's framing was that the announcement was met with caution by some experts who suggested the company oversold its significance. Not all reaction was negative: Stanley Qi, a bioengineer at Stanford, told Al Jazeera it was an "incredibly exciting" example of how AI can detect complex biological patterns. On reproducibility, a material fact the post omits. Anthropic ran the same campaign ten more times; no rerun read the DNA upstream of the enzyme, and all ten missed the array, which the authors attribute to the size of the search and the agents' unpredictable behaviour.